Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Merck Kgaa ADR

(OTHER OTC: MKKGY)
Add to Portfolio
+0.0500 (+0.21%)
as of Oct 18, 2019

Last 23.6900
Change +0.0500 (+0.21%)
Open 23.6200
Prev. Close 23.6400
Today's Range
23.5200
23.6900
52wk Range
19.2000
23.6900
Volume 11,500
Avg Volume 9,580
Sector All Sectors By Industry

Perfomance Comparison

Name Today 3-Month 1-Year
MKKGY +0.21% +11.85% +11.82%
DJIA -0.95% +1.49% +5.48%
S&P 500 -0.39% +1.64% +7.85%

Key Statistics

Annual EPS N/A
Dividend Yield N/A
P/E Ratio N/A
Market Capitalization, $K N/A
Weighted Alpha +19.80
Standard Deviation +0.20
Profit Margin N/A
Beta N/A

Growth Rates

YTD +14.14%
1-Year +9.70%

Opinion

Sell Hold Buy

Recent Headlines

EMD Serono Announces JAMA Publication of Phase II

PR Newswire via COMTEX - Tue Oct 08, 11:24AM EDT
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, today announced that results from FORWARD, a five-year, multicenter Phase II study of sprifermin, a recombinant human fibroblast(full story)
MKKGY: 23.6900 (+0.0500)

Sutro Biopharma to Receive Milestone Payment for Novel

PR Newswire via COMTEX - Tue Oct 08, 07:00AM EDT
Sutro Biopharma, Inc. (NASDAQ: STRO) today announced that it has achieved a milestone under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany and is entitled to receive a milest(full story)
MKKGY: 23.6900 (+0.0500), STRO: 9.98 (+0.03)

Merck KGaA, Darmstadt, Germany, Completes Acquisition

BusinessWire via COMTEX - Mon Oct 07, 08:27AM EDT
Versum Materials, Inc., a leading materials supplier to the semiconductor industry, today announced that it has completed the announced transaction with Merck KGaA, Darmstadt, Germany.(full story)
MKKGY: 23.6900 (+0.0500), VSM: 52.99 (+0.01), APD: 214.88 (+0.51)

Benefitting From Expanded Access in Europe, Roche's

PR Newswire via COMTEX - Mon Oct 07, 04:47AM EDT
Expanded access to Merck KGaA's Mavenclad and Roche's Ocrevus in Europe has significantly shifted neurologists' reported disease-modifying therapy (DMT) treatment patterns among multiple sclerosis (MS) patients. Data from 250 EU n(full story)
MKKGY: 23.6900 (+0.0500), NVS: 86.88 (-0.35)

Mercury Systems Set to Join S&P MidCap 400;

PR Newswire via COMTEX - Wed Oct 02, 06:15PM EDT
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600:(full story)
MKKGY: 23.6900 (+0.0500), MRCY: 71.83 (-1.04), VSM: 52.99 (+0.01), CLF: 6.92 (-0.09), EPRT: 24.75 (+0.48), NCI: 27.99 (unch), SPGI: 250.48 (-2.52)